Loading…

Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation

A few scores predicting the short-term risk of mortality in Systemic sclerosis (SSc) have been reported to date. Our study aimed to create a predictive 15-year all-cause mortality score at the time of the diagnosis of SSc. The study was based on the Spanish Scleroderma Registry (RESCLE). The cohort...

Full description

Saved in:
Bibliographic Details
Published in:Autoimmunity reviews 2020-05, Vol.19 (5), p.102507, Article 102507
Main Authors: Rubio-Rivas, Manuel, Corbella, Xavier, Guillén-del-Castillo, Alfredo, Tolosa Vilella, Carles, Colunga Argüelles, Dolores, Argibay, Ana, Vargas Hitos, José Antonio, Todolí Parra, José Antonio, González-Echávarri, Cristina, Ortego-Centeno, Norberto, Trapiella Martínez, Luis, Rodríguez Carballeira, Mónica, Marín Ballvé, Adela, Pla Salas, Xavier, Perales Fraile, Isabel, Chamorro, Antonio-J, Madroñero Vuelta, Ana Belén, Freire, Mayka, Ruiz Muñoz, Manuel, González García, Andrés, Pons Martín del Campo, Isaac, Sánchez García, María Esther, Bernal Bello, David, Espinosa, Gerard, García Hernández, Francisco José, Sáez Comet, Luis, Ríos Blanco, Juan José, Fernández de la Puebla Giménez, Rafael Ángel, Sánchez Trigo, Sabela, Fonollosa Pla, Vicent, Simeón Aznar, Carmen Pilar
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A few scores predicting the short-term risk of mortality in Systemic sclerosis (SSc) have been reported to date. Our study aimed to create a predictive 15-year all-cause mortality score at the time of the diagnosis of SSc. The study was based on the Spanish Scleroderma Registry (RESCLE). The cohort was split up in derivation (DC) and validation cohort (VC). A multivariate analysis to detect variables related to all-cause mortality within the first 15 years from SSc diagnosis was performed, assigning points to the rounded beta values to create the score (RESCLESCORE). 1935 SSc patients were included. The variables in the final model were as follows: age at diagnosis (+2 points > 65 years-old), male gender (+1 point), lcSSc subset (−1 point), mode of onset other than Raynaud's (+1 point), cancer (+1 point) and visceral involvement, such as ILD (+1 point), PAH (+1 point), heart (+1 point) and renal involvement (+2 points). Autoantibodies did not achieve statistical significance in the multivariate analysis. The 3 categories of risk to predict 15-year all-cause mortality at the time of diagnosis were as follows: low risk (5% vs. 7%, p = .189), intermediate risk (26.5% vs. 25.5%, p = .911) and high risk (47.8% vs. 59%, p = .316). The AUC was 0.799 (DC) vs. 0.778 (VC) (p = .530). In conclusion, the RESCLESCORE demonstrated an excellent ability to categorize SSc patients at the time of diagnosis in separate 15-year all-cause mortality risk strata at the time of diagnosis. •New score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis.•3-risk strata categories.•AUC 0 0.799.
ISSN:1568-9972
1568-9972
DOI:10.1016/j.autrev.2020.102507